News from diamyd medical ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 16, 2020, 07:03 ET Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about...


Sep 14, 2020, 11:38 ET Phase IIb topline results demonstrate a significant treatment effect of Diamyd® in a previously identified genetic subgroup of individuals with type 1 diabetes

Diamyd Medical today announced the topline results from the placebo-controlled Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd®...


Aug 05, 2020, 03:20 ET Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd® in genetically defined subgroups of type 1 diabetes

Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a...


Jun 24, 2020, 02:54 ET Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020

Developing therapies for type 1 diabetes Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. Further...


May 04, 2020, 07:25 ET Promising Findings From the First Part of a Clinical Trial With Remygen®

The initial safety and dose escalation part of the Phase I/II trial ReGenerate-1 with Remygen® in individuals with long-term type 1 diabetes today...


Apr 24, 2020, 07:00 ET Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®

The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in...


Apr 16, 2020, 13:01 ET Diamyd Medical Opens up for Vaccine Manufacturing in Umeå, Sweden

A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for...


Dec 20, 2019, 11:50 ET Positive Top-line Results From I/II Trial With Intralymphatic Diamyd®

Diamyd Medical announced today, when all 12 patients have been followed throughout the 30-month period in the open-label trial DIAGNODE-1, that the...


Dec 12, 2019, 15:46 ET Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and ...


Oct 15, 2019, 06:00 ET Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA

The agreement with the Norwegian University of Science and Technology in Trondheim (NTNU) refers to a first, investigator initiated clinical Phase II ...


Sep 09, 2019, 09:14 ET Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®

A feasibility study performed as a Master Thesis at Uppsala University and supervised by Diamyd Medical, supports the use of ultrasound guided...


Jun 04, 2019, 02:36 ET New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®

The first seven patients that have now been followed for the entire 30-month period in DIAGNODE-1 continue to show a positive clinical course and are ...


May 29, 2019, 09:07 ET The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1

The approval by the Swedish MPA entails that ReGenerate-1, with Diamyd Medical's GABA-based investigational drug Remygen®, will be expanded from the...


Mar 26, 2019, 03:45 ET Diamyd Medical Announces Strategic Activities for 2019 and 2020

With experience from clinical trials in more than 1,000 patients with the diabetes vaccine Diamyd®, preparations for a Conditional Marketing...


Dec 06, 2018, 02:31 ET Diamyd Medical Raises SEK 58.4 Million in Funds Through Redemption of Warrants

During 1 to 30 November 2018, holders of warrants of series TO 1 B and TO 2 A of Diamyd Medical AB have been able to subscribe for shares through...


Oct 23, 2018, 02:52 ET New Immunological Results That Support Intralymphatic Treatment With Diamyd® to be Presented at the Immunology of Diabetes Society Congress

New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the...